ChoironeX GalKO Porcine Thymokidney Xenotransplantation in ESRD

Phase 1, open-label, single-arm trial in end stage renal disease (ESRD), sponsored by Xeno Holdings. Primary endpoints: Incidence and severity of adverse events, serious adverse events, and adverse events of special interest at 6 months and Overall survival of the recipient without the need for chronic dialysis at 6 months. Started Oct 2026; status: recruiting.